Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 12 nov 2014 - 07:58
- Statutory name Galapagos N.V.
- Title Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
- Comments Mechelen, Belgium 12 November 2014: Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that recruitment of rheumatoid arthritis (RA) patients for the Darwin 1 Phase 2B study with GLPG0634 has been completed.
Date last update: 29 October 2020